As oncology drugs save or extend the lives of many more patients than anyone could have imagined a few years ago, a new challenge has emerged in the wake of their approval: Selling them to patients scared about their prognosis and alternately ignorant of and skeptical about recent breakthroughs in treatment.
If asked, some will equivocate and say they get their facts from medical journals and from published studies, but never from those pesky misleading ads.
AMA votes to require disclosure of drug prices in DTC ads